Neuroendocrine tumours of the urinary system and male genital organs: clinical significance

Mazzucchelli, Roberta; Morichetti, Doriana; López-Beltrán, Antonio; Liu, Cheng; Scarpelli, Marina; Kirkali, Ziya; Montironi, Rodolfo

doi:10.1111/j.1464-410x.2009.08451.x

Cited by 91 publications

(102 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is a high-grade tumor that consists of large nests and ribbons of cells with abundant pale to amphiphilic cytoplasm, large nuclei, and prominent nucleoli along with high mitotic activity and foci of necrosis [12,13]. LCNEC is strongly positive for CD56, CD57, Chromogranin A, synaptophysin, and P504S/alpha methylacyl CoA racemase.…”

Section: Discussionmentioning

confidence: 99%

An Unusual Case of Resistant Hypokalaemia in a Patient With Large Bowel Obstruction Secondary to Neuroendocrine Carcinoma of the Prostate

Ponnuswamy

Thiyagarajan

Bagul

et al. 2017

International Journal of Surgery

View full text Add to dashboard Cite

Neuroendocrine Carcinoma of the Prostate (NECP) is rare and only few cases have been reported, constituting less than 0.5% of prostatic malignancies. We report a rare case of large bowel obstruction from NECP posing a further challenge in management due to resistant hypokalaemia. A 70-year-old man presented with clinical signs of large bowel obstruction who was known to have prostatic carcinoma three years ago, treated initially with hormone therapy then chemoradiation. The blood profile showed a severe hypokalaemia and CT scan revealed liver and lung metastases apart from confirming large bowel obstruction from local invasion of NECP. Severe hypokalaemia was believed to be caused by paraneoplastic syndrome from tumor burden or by recent administration of Etoposide. Intensive potassium correction through a central venous access in maximal doses of 150 mmol/24 hours under cardiac monitoring finally raised serum potassium to 3.8 mmol/L. This safe period allowed us to perform a trephine colostomy at the left iliac fossa. The postoperative period was relatively uneventful. This first case report is presenting a rare cause of large bowel obstruction from a neuroendocrine carcinoma of prostate and highlights the importance of an early, intensive correction of electrolytes in patients with large tumor burden from NECP.

show abstract

Section: Discussionmentioning

confidence: 99%

An Unusual Case of Resistant Hypokalaemia in a Patient With Large Bowel Obstruction Secondary to Neuroendocrine Carcinoma of the Prostate

Ponnuswamy

Thiyagarajan

Bagul

et al. 2017

International Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…Less frequently, large cell neuroendocrine carcinoma is seen 21,22 . Some authors 23,24 claim that neuroendocrine carcinoma of the renal pelvis is more frequently associated with transitional cell carcinoma, adenocarcinoma or squamous cell carcinoma than with the same tumors arising in the renal parenchyma.…”

Section: Discussionmentioning

confidence: 99%

Primary neuroendocrine carcinoma of the kidney

Jana¹,

Macák²,

Brzula³

et al. 2013

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Background. The objective of the study was to report a rare case of primary neuroendocrine carcinoma of the right kidney in a 36 year old male. Methods. The patient was clinically assessed; CT and OctreoScan scintigraphy were performed and levels of 5-HIAA, vanillylmandelic acid and NSE were determined. The tumor and metastases were histologically and immunohistochemically examined. Results. The imaging methods showed a cystic tumor in the lower pole of the right kidney. Macroscopically, the entire tumor was sized 8x8x7 cm. Histologically, it was made up of ribbon-line or trabecular patterns of tumor cells. Occasional adenomatoid and cystic structures were present. The tumor cell nuclei were round or oval, with no irregularities and fine lumpy chromatin. The mitotic count was < 1 /10HPF and the proliferation marker Ki-67 was < 1 % of tumor cells. Immunohistochemically, the tumor cells were positive with antibodies against chromogranin A, synaptophysin, CD56 (focally), cytokeratins AE1-AE3 (focally), vimentin (most cells), glucagon (focally), and pancreatic polypeptide (PP; focally). Antibodies against serotonin, somatostatin, gastrin, vasoactive intestinal polypeptide (VIP) and calcitonin did not react with the tumor. The results of biochemical markers (5-HIAA, vanillylmandelic acid and NSE) did not correlate with development or treatment of the tumor. Conclusions. Primary neuroendocrine carcinoma of the kidney was diagnosed both histologically and immunohistochemically. The patient was clinically investigated using CT and OctreoScan scintigraphy. Within two years from nephrectomy, metastases were found in the right humerus and retrocaval lymph nodes. The metastatic lesions were surgically removed. Currently, the patient's condition is good, with no tumor progression detected.

show abstract

“…It is estimated that direct relation exists between bladder cancer occurrence and age in such a way that the common time of diagnosis is around 70 for both sexes. [1,2] Successful treatment of bladder cancer carcinoma depends on specific diagnostic approaches and early detection. Therefore, improving molecular techniques such as polymerase chain reaction (PCR) and single-strand conformation polymorphism (SSCP) would undoubtedly develop understanding of molecular abnormalities related to urothelial malignant transformation.…”

Section: Introductionmentioning

confidence: 99%

Detection of p53 exon 9 gene mutation in bladder cancer by polymerase chain reaction-single-strand conformation polymorphism method

et al. 2017

View full text Add to dashboard Cite

Introduction: Urinary bladder cancer is the fourth most common diagnosed malignancy in men and the tenth in women worldwide. The successful treatment depends on early detection and specific diagnostic approaches. Mutations in the p53 tumor suppressor gene (TP53) are very common among the cancers, especially in bladder cancer that p53 mutation is identified in around 60 percents. Aims: In this study, we aim to detect p53 mutation in bladder cancer patients in Kermanshah city of Iran. Materials and Methods: Thirty paraffin-embedded specimens were obtained from bladder cancer patients. They were reviewed by pathologists for substantial amounts of neoplastic tissue. PCR-SSCP technique was used followed by standard silver staining to analyze TP53 exon 9 gene mutations in tumor samples. RESULTS: Polyacrylamide gel analysis represented mutations in 2 cases (6.7%) that were classified as p53-positive, and there were no mutations in 28 cases (93.3%) that were classified as p53-negative. No significant correlation observed between p53 mutation and histological grade, tumor stage, muscular propria status, patient sex, and age. Conclusion: These data are the first report on the p53 abnormalities in bladder cancer patients from Kermanshah. We can suppose that the percentage of p53 exon 9 mutation is low in bladder cancer patients from western Iran. However, further studies on a large number of tissue specimens, if possible, help to verify the obtained results.

show abstract

Neuroendocrine tumours of the urinary system and male genital organs: clinical significance

Cited by 91 publications

References 36 publications

An Unusual Case of Resistant Hypokalaemia in a Patient With Large Bowel Obstruction Secondary to Neuroendocrine Carcinoma of the Prostate

An Unusual Case of Resistant Hypokalaemia in a Patient With Large Bowel Obstruction Secondary to Neuroendocrine Carcinoma of the Prostate

Primary neuroendocrine carcinoma of the kidney

Detection of p53 exon 9 gene mutation in bladder cancer by polymerase chain reaction-single-strand conformation polymorphism method

Contact Info

Product

Resources

About